Head and neck cancer

Nuclear Oncology: Pathophysiology and Clinical Applications

Volumn , Issue , 2013, Pages 269-295

  Schoder H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Head and neck cancer in PET imaging; PET imaging in head and neck cancer; Radiotracers in head and neck cancer; Squamous cell carcinomas of head and neck

Indexed keywords

EID: 84919721271     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-48894-3_10     Document Type: Chapter

References (141)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60(5):277–300.
2. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92:709–20.
3. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11:9–22.
4. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342–50.
5. Marur S, D’Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11:781–9.
6. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35.
7. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100:261–9.
8. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 2008;26:3128–37.
9. Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol. 2008;26:3138–46.
10. Chuang AY, Chuang TC, Chang S, et al. Presence of HPV DNA in convalescent salivary rinses is an adverse prognostic marker in head and neck squamous cell carcinoma. Oral Oncol. 2008;44:915–9.
11. Tabor MP, Brakenhoff RH, van Houten VM, et al. Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res. 2001;7: 1523–32.
12. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Kummer JA, Leemans CR, Braakhuis BJ. Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clin Cancer Res. 2004;10:3607–13.
13. Schoder H, Fury M, Lee N, Kraus D. PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med. 2009;50 Suppl 1:74S–88S.
14. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22:69–76.
15. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–8.
16. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92–8.
17. McHam SA, Adelstein DJ, Rybicki LA, et al. Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer? Head Neck. 2003;25:791–8.
18. Brizel DM, Prosnitz RG, Hunter S, et al. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;58:1418–23.
19. Frank DK, Hu KS, Culliney BE, et al. Planned neck dissection after concomitant radiochemotherapy for advanced head and neck cancer. Laryngoscope. 2005;115:1015–20.
20. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350–6.
21. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol. 2006;24:4170–6.
22. Cohen EE. Role of epidermal growth factor receptor pathwaytargeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24:2659–65.
23. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–78.
24. Papaspyrou G, Werner JA, Dietz A. Pharmacotherapy for squamous-cell carcinoma of the head and neck. Expert Opin Pharmacother. 2011;12:397–409.
25. Argiris A, Karamouzis MV, Gooding WE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 2011;29:1140–45.
26. Curtin HD, Ishwaran H, Mancuso AA, Dalley RW, Caudry DJ, McNeil BJ. Comparison of CT and MR imaging in staging of neck metastases. Radiology. 1998;207:123–30.
27. Branstetter 4th BF, Blodgett TM, Zimmer LA, et al. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology. 2005;235:580–6.
28. Schoder H, Yeung HW, Gonen M, Kraus D, Larson SM. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology. 2004;231:65–72.
29. Chin SC, Edelstein S, Chen CY, Som PM. Using CT to localize side and level of vocal cord paralysis. AJR Am J Roentgenol. 2003;180:1165–70.
30. Komissarova M, Wong KK, Piert M, Mukherji SK, Fig LM. Spectrum of 18 F-FDG PET/CT findings in oncology-related recurrent laryngeal nerve palsy. AJR Am J Roentgenol. 2009;192:288–94.
31. Annino Jr DJ, MacArthur CJ, Friedman EM. Vincristine-induced recurrent laryngeal nerve paralysis. Laryngoscope. 1992;102: 1260–2.
32. Graham MM, Menda Y. Positron emission tomography/computed tomography imaging of head and neck tumors: an atlas. Semin Nucl Med. 2005;35:220–52.
33. Gupta S, Henningsen JA, Wallace MJ, et al. Percutaneous biopsy of head and neck lesions with CT guidance: various approaches and relevant anatomic and technical considerations. Radiographics. 2007;27:371–90.
34. Bohuslavizki KH, Klutmann S, Kroger S, et al. FDG PET detection of unknown primary tumors. J Nucl Med. 2000;41:816–22.
35. Fogarty GB, Peters LJ, Stewart J, Scott C, Rischin D, Hicks RJ. The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor. Head Neck. 2003;25:138–45.
36. Gutzeit A, Antoch G, Kuhl H, et al. Unknown primary tumors: detection with dual-modality PET/CT–initial experience. Radiology. 2005;234:227–34.
37. Johansen J, Buus S, Loft A, et al. Prospective study of 18 FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study. Head Neck. 2008;30:471–8.
38. Johansen J, Eigtved A, Buchwald C, Theilgaard SA, Hansen HS. Implication of 18 F- fluoro-2-deoxy- d -glucose positron emission tomography on management of carcinoma of unknown primary in the head and neck: a Danish cohort study. Laryngoscope. 2002;112:2009–14.
39. Jungehulsing M, Scheidhauer K, Damm M, et al. 2[18F]- fluoro-2- deoxy- d -glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg. 2000;123:294–301.
40. Kole AC, Nieweg OE, Pruim J, et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer. 1998;82:1160–6.
41. Miller FR, Karnad AB, Eng T, Hussey DH, Stan McGuff H, Otto RA. Management of the unknown primary carcinoma: long-term follow-up on a negative PET scan and negative panendoscopy. Head Neck. 2008;30:28–34.
42. Roh JL, Kim JS, Lee JH, et al. Utility of combined 18 F- fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors. Oral Oncol. 2009;45:218–24.
43. Wartski M, Le Stanc E, Gontier E, et al. In search of an unknown primary tumour presenting with cervical metastases: performance of hybrid FDG-PET-CT. Nucl Med Commun. 2007;28: 365–71.
44. Wong WL, Saunders M. The impact of FDG PET on the management of occult primary head and neck tumours. Clin Oncol (R Coll Radiol). 2003;15:461–6.
45. Yabuki K, Tsukuda M, Horiuchi C, Taguchi T, Nishimura G. Role of 18 F-FDG PET in detecting primary site in the patient with primary unknown carcinoma. Eur Arch Otorhinolaryngol. 2010;267:1785–92.
46. Hannah A, Scott AM, Tochon-Danguy H, et al. Evaluation of 18 F- fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg. 2002;236:208–17.
47. O’Brien CJ, Smith JW, Soong SJ, Urist MM, Maddox WA. Neck dissection with and without radiotherapy: prognostic factors, patterns of recurrence, and survival. Am J Surg. 1986;152: 456–63.
48. Layland MK, Sessions DG, Lenox J. The in fluence of lymph node metastasis in the treatment of squamous cell carcinoma of the oral cavity, oropharynx, larynx, and hypopharynx: N0 versus N+. Laryngoscope. 2005;115:629–39.
49. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer. 1994;73:187–90.
50. Johnson JT, Myers EN, Bedetti CD, Barnes EL, Schramm Jr VL, Thearle PB. Cervical lymph node metastases. Incidence and implications of extracapsular carcinoma. Arch Otolaryngol. 1985;111:534–7.
51. Jones AS, Roland NJ, Field JK, Phillips DE. The level of cervical lymph node metastases: their prognostic relevance and relationship with head and neck squamous carcinoma primary sites. Clin Otolaryngol Allied Sci. 1994;19:63–9.
52. Stell PM, Morton RP, Singh SD. Cervical lymph node metastases: the significance of the level of the lymph node. Clin Oncol. 1983;9:101–7.
53. van den Brekel MW, Stel HV, Castelijns JA, et al. Cervical lymph node metastasis: assessment of radiologic criteria. Radiology. 1990;177:379–84.
54. Adams S, Baum RP, Stuckensen T, Bitter K, Hor G. Prospective comparison of 18 F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med. 1998;25:1255–60.
55. Kau RJ, Alexiou C, Laubenbacher C, Werner M, Schwaiger M, Arnold W. Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting. Arch Otolaryngol Head Neck Surg. 1999;125:1322–8.
56. Stuckensen T, Kovacs AF, Adams S, Baum RP. Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI. J Craniomaxillofac Surg. 2000;28:319–24.
57. Dammann F, Horger M, Mueller-Berg M, et al. Rational diagnosis of squamous cell carcinoma of the head and neck region: comparative evaluation of CT, MRI, and 18 FDG PET. AJR Am J Roentgenol. 2005;184:1326–31.
58. Roh JL, Yeo NK, Kim JS, et al. Utility of 2-[18F] fluoro-2-deoxyd -glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma. Oral Oncol. 2007;43:887–93.
59. Ng SH, Yen TC, Liao CT, et al. 18 F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. J Nucl Med. 2005;46: 1136–43.
60. Liao CT, Wang HM, Huang SF, et al. PET and PET/CT of the neck lymph nodes improves risk prediction in patients with squamous cell carcinoma of the oral cavity. J Nucl Med. 2011;52:180–7.
61. Kyzas PA, Evangelou E, Denaxa-Kyza D, Ioannidis JP. 18 F- fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst. 2008;100:712–20.
62. Stambuk HE, Karimi S, Lee N, Patel SG. Oral cavity and oropharynx tumors. Radiol Clin North Am. 2007;45:1–20.
63. Ferlito A, Shaha AR, Silver CE, Rinaldo A, Mondin V. Incidence and sites of distant metastases from head and neck cancer. ORL J Otorhinolaryngol Relat Spec. 2001;63:202–7.
64. Brouwer J, de Bree R, Hoekstra OS, et al. Screening for distant metastases in patients with head and neck cancer: is chest computed tomography sufficient? Laryngoscope. 2005;115:1813–7.
65. Erkal HS, Mendenhall WM, Amdur RJ, Villaret DB, Stringer SP. Synchronous and metachronous squamous cell carcinomas of the head and neck mucosal sites. J Clin Oncol. 2001;19:1358–62.
66. Schwartz DL, Rajendran J, Yueh B, et al. Staging of head and neck squamous cell cancer with extended-field FDG-PET. Arch Otolaryngol Head Neck Surg. 2003;129:1173–8.
67. Schmid DT, Stoeckli SJ, Bandhauer F, et al. Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck. Laryngoscope. 2003;113:888–91.
68. Haerle SK, Strobel K, Hany TF, Sidler D, Stoeckli SJ. 18 F-FDGPET/CT versus panendoscopy for the detection of synchronous second primary tumors in patients with head and neck squamous cell carcinoma. Head Neck. 2010;32:319–25.
69. Strobel K, Haerle SK, Stoeckli SJ, et al. Head and neck squamous cell carcinoma (HNSCC)–detection of synchronous primaries with 18 F-FDG-PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:919–27.
70. Kim SY, Roh JL, Yeo NK, et al. Combined 18 F- fluorodeoxyglucosepositron emission tomography and computed tomography as a primary screening method for detecting second primary cancers and distant metastases in patients with head and neck cancer. Ann Oncol. 2007;18:1698–703.
71. Morris LG, Sikora AG, Patel SG, Hayes RB, Ganly I. Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. J Clin Oncol. 2011;29:739–46.
72. Choi JY, Lee KS, Kwon OJ, et al. Improved detection of second primary cancer using integrated [18F]- fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging. J Clin Oncol. 2005;23:7654–9.
73. Uyl-de Groot CA, Senft A, de Bree R, Leemans CR, Hoekstra OS. Chest CT and whole-body 18 F-FDG PET are cost-effective in screening for distant metastases in head and neck cancer patients. J Nucl Med. 2010;51:176–82.
74. Scott AM, Gunawardana DH, Bartholomeusz D, Ramshaw JE, Lin P. PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective study. J Nucl Med. 2008;49: 1593–600.
75. Porceddu SV, Jarmolowski E, Hicks RJ, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck. 2005;27:175–81.
76. Yao M, Smith RB, Graham MM, et al. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys. 2005;63:991–9.
77. Andrade RS, Heron DE, Degirmenci B, et al. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys. 2006;65:1315–22.
78. Tan A, Adelstein DJ, Rybicki LA, et al. Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy. Arch Otolaryngol Head Neck Surg. 2007;133:435–40.
79. Nayak JV, Walvekar RR, Andrade RS, et al. Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT. Laryngoscope. 2007; 117:2129–34.
80. Ong SC, Schoder H, Lee NY, et al. Clinical utility of 18 F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer. J Nucl Med. 2008;49:532–40.
81. Yao M, Smith RB, Hoffman HT, et al. Clinical significance of postradiotherapy [18F]- fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report. Int J Radiat Oncol Biol Phys. 2009;74:9–14.
82. Moeller BJ, Rana V, Cannon BA, et al. Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol. 2009;27:2509–15.
83. Porceddu SV, Pryor DI, Burmeister E, et al. Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck. 2011;33:1675–82.
84. Greven KM, Williams 3rd DW, McGuirt Sr WF, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck. 2001;23:942–6.
85. Ryan WR, Fee Jr WE, Le QT, Pinto HA. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope. 2005;115:645–50.
86. Forrester HB, Albright N, Ling CC, Dewey WC. Computerized video time-lapse analysis of apoptosis of REC:Myc cells X-irradiated in different phases of the cell cycle. Radiat Res. 2000;154:625–39.
87. Luce A, Courtin A, Levalois C, et al. Death receptor pathways mediate targeted and non-targeted effects of ionizing radiations in breast cancer cells. Carcinogenesis. 2009;30:432–9.
88. Dornfeld K, Hopkins S, Simmons J, et al. Posttreatment FDG-PET uptake in the supraglottic and glottic larynx correlates with decreased quality of life after chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2008;71:386–92.
89. Ferlito A, Corry J, Silver CE, Shaha AR, Thomas Robbins K, Rinaldo A. Planned neck dissection for patients with complete response to chemoradiotherapy: a concept approaching obsolescence. Head Neck. 2010;32:253–61.
90. Wee JT, Anderson BO, Corry J, et al. Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10:1086–92.
91. Schoder H, Moskowitz C. PET imaging for response assessment in lymphoma: potential and limitations. Radiol Clin North Am. 2008;46:225–41. viii.
92. Weber WA, Wieder H. Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging. 2006;33 Suppl 1:27–37.
93. Brun E, Kjellen E, Tennvall J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 2002;24:127–35.
94. Shintani SA, Foote RL, Lowe VJ, Brown PD, Garces YI, Kasperbauer JL. Utility of PET/CT imaging performed early after surgical resection in the adjuvant treatment planning for head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70:322–9.
95. Goodwin Jr WJ. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope. 2000;110(3 Pt 2 Suppl 93):1–18.
96. Lapela M, Eigtved A, Jyrkkio S, et al. Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer. Eur J Cancer. 2000;36: 858–67.
97. Kunkel M, Forster GJ, Reichert TE, et al. Detection of recurrent oral squamous cell carcinoma by [18F]-2- fluorodeoxyglucosepositron emission tomography: implications for prognosis and patient management. Cancer. 2003;98:2257–65.
98. Lonneux M, Lawson G, Ide C, Bausart R, Remacle M, Pauwels S. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope. 2000;110:1493–7.
99. Wong RJ, Lin DT, Schoder H, et al. Diagnostic and prognostic value of [18F] fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol. 2002;20:4199–208.
100. Kubota K, Yokoyama J, Yamaguchi K, et al. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging. 2004;31:590–5.
101. Abgral R, Querellou S, Potard G, et al. Does 18 F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med. 2009;50:24–9.
102. Goerres GW, Schmid DT, Bandhauer F, et al. Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2004;130:105–9. discussion 120–1.
103. Salaun PY, Abgral R, Querellou S, et al. Does 18 fluoro fluorodeoxyglucose positron emission tomography improve recurrence detection in patients treated for head and neck squamous cell carcinoma with negative clinical follow-up? Head Neck. 2007;29:1115–20.
104. Lowe VJ, Boyd JH, Dunphy FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol. 2000;18:651–8.
105. Haberkorn U, Strauss LG, Reisser C, et al. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med. 1991;32:1548–55.
106. Jacob R, Welkoborsky HJ, Bittinger F, Mann WJ, Amedee R. Histological grading, growth fraction and DNA-ploidy as criteria for the treatment of pharyngeal and supraglottic squamous cell carcinomas: a preliminary, prospective study. ORL J Otorhinolaryngol Relat Spec. 2001;63:314–20.
107. Minn H, Clavo AC, Grenman R, Wahl RL. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med. 1995;36:252–8.
108. Allal AS, Dulguerov P, Allaoua M, et al. Standardized uptake value of 2-[18F] fluoro-2-deoxy- d -glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol. 2002;20:1398–404.
109. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F] fluoro-2- deoxy- d -glucose. Int J Radiat Oncol Biol Phys. 2004;59: 1295–300.
110. Kunkel M, Reichert TE, Benz P, et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer. 2003;97:1015–24.
111. Chung MK, Jeong HS, Park SG, et al. Metabolic tumor volume of [18F]- fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res. 2009;15:5861–8.
112. Farrag A, Ceulemans G, Voordeckers M, Everaert H, Storme G. Can 18 F-FDG-PET response during radiotherapy be used as a predictive factor for the outcome of head and neck cancer patients? Nucl Med Commun. 2010;31:495–501.
113. Kim SY, Roh JL, Kim MR, et al. Use of 18 F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med. 2007;48:752–7.
114. La TH, Filion EJ, Turnbull BB, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009;74:1335–41.
115. Liao CT, Chang JT, Wang HM, et al. Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys. 2009;73:764–71.
116. Machtay M, Natwa M, Andrel J, et al. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck. 2009;31:195–201.
117. Suzuki H, Hasegawa Y, Terada A, et al. FDG-PET predicts survival and distant metastasis in oral squamous cell carcinoma. Oral Oncol. 2009;45:569–73.
118. Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer. 2002;86:512–6.
119. Liao CT, Chang JT, Wang HM, et al. Preoperative [18F] fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes predicts neck cancer control and survival rates in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys. 2009;74:1054–61.
120. Chong VF, Ong CK. Nasopharyngeal carcinoma. Eur J Radiol. 2008;66:437–47.
121. Liu FY, Lin CY, Chang JT, et al. 18 F-FDG PET can replace conventional work-up in primary M staging of nonkeratinizing nasopharyngeal carcinoma. J Nucl Med. 2007;48:1614–9.
122. Ng SH, Chan SC, Yen TC, et al. Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. Eur J Nucl Med Mol Imaging. 2009;36:12–22.
123. Chan SC, Yen TC, Ng SH, et al. Differential roles of 18 F-FDG PET in patients with locoregional advanced nasopharyngeal carcinoma after primary curative therapy: response evaluation and impact on management. J Nucl Med. 2006;47:1447–54.
124. Comoretto M, Balestreri L, Borsatti E, Cimitan M, Franchin G, Lise M. Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy: comparison of MR imaging and FDG PET/CT. Radiology. 2008;249:203–11.
125. Ng SH, Chan SC, Yen TC, et al. Comprehensive imaging of residual/recurrent nasopharyngeal carcinoma using whole-body MRI at 3T compared with FDG-PET-CT. Eur Radiol. 2010;20:2229–40.
126. Ng SH, Joseph CT, Chan SC, et al. Clinical usefulness of 18 F-FDG PET in nasopharyngeal carcinoma patients with questionable MRI findings for recurrence. J Nucl Med. 2004;45:1669–76.
127. Xie P, Yue JB, Fu Z, Feng R, Yu JM. Prognostic value of 18 F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma. Ann Oncol. 2010;21:1078–82.
128. Krabbe CA, van der Werff-Regelink G, Pruim J, van der Wal JE, Roodenburg JL. Detection of cervical metastases with 11 C-tyrosine PET in patients with squamous cell carcinoma of the oral cavity or oropharynx: a comparison with 18 F-FDG PET. Head Neck. 2010;32:368–74.
129. Balogova S, Perie S, Kerrou K, et al. Prospective comparison of FDG and FET PET/CT in patients with head and neck squamous cell carcinoma. Mol Imaging Biol. 2008;10:364–73.
130. Pauleit D, Zimmermann A, Stoffels G, et al. 18 F-FET PET compared with 18 F-FDG PET and CT in patients with head and neck cancer. J Nucl Med. 2006;47:256–61.
131. Ito K, Yokoyama J, Kubota K, Morooka M, Shiibashi M, Matsuda H. 18 F-FDG versus 11 C-choline PET/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy: the time period during which PET/CT can reliably detect non-recurrence. Eur J Nucl Med Mol Imaging. 2010;37:1318–27.
132. Lee N, Nehmeh S, Schoder H, et al. Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;75:101–8.
133. Grosu AL, Souvatzoglou M, Roper B, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69: 541–51.
134. Minagawa Y, Shizukuishi K, Koike I, et al. Assessment of tumor hypoxia by 62 Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study. Ann Nucl Med. 2011;25: 339–45.
135. Menda Y, Boles Ponto LL, Dornfeld KJ, et al. Kinetic analysis of 3 ¢ -deoxy-3 ¢ - 18 F- fluorothymidine (18 F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy. J Nucl Med. 2009;50:1028–35.
136. Troost EG, Vogel WV, Merkx MA, et al. 18 F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007;48: 726–35.
137. Troost EG, Bussink J, Hoffmann AL, Boerman OC, Oyen WJ, Kaanders JH. 18 F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med. 2010;51:866–74.
138. Daisne JF, Duprez T, Weynand B, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology. 2004;233:93–100.
139. Hoeben BA, Kaanders JH, Franssen GM, et al. PET of hypoxia with 89 Zr-labeled cG250-F(ab’)2 in head and neck tumors. J Nucl Med. 2010;51:1076–83.
140. Postema EJ, McEwan AJ, Riauka TA, et al. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]- fluoroarabinofuranosyl)-2-nitroimidazole (18 F-FAZA). Eur J Nucl Med Mol Imaging. 2009;36:1565–73.
141. Schoder H, Ong SC. Fundamentals of molecular imaging: rationale and applications with relevance for radiation oncology. Semin Nucl Med. 2008;38:119–28.